normal  medium  large

The following are active clinical trials which you can discuss with your healthcare team or call (631) 638-0846.

Study: Pfizer-A5481008-A Randomized, Multicenter, Double-Blind Phase 3 Study of PD-0332991 (Oral CDK 4/6 inhibitor) plus Letrozole versus Placebo Plus Letrozole for the treatment of postmenopausal women with ER (+), HER2 (-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.
Principal Investigator: Janice Lu, MD
Department:
Start Date: 7/31/2013
End Date:

Study: NSABP B-47:  A randomized Phase III Trial of adjuvant therapy comparing chemotherapy alone (six cycles of Docetaxel plus Cyclophosphamide followed by weekly Paclitaxel) to chemotherapy plus Trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer
Principal Investigator: A. Kudelka, MD
Department: 
Start Date: 5/27/11
End Date:

Study: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiaton Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situa Resected by NSAPB B-43
Principal Investigator: Jules Cohen, MD
Department: 
Start Date: 10/3/11
End Date:

Study: A Phase II Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-2 Positive Nodes, Homrone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less - S1007
Principal Investigator: Andrzej Kudelka, MD
Department: 
Start Date: 7/27/11
End Date: